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Today’s novel therapeutic approaches should be evalu-ated for clinical, but also for their economic outcome, because value of health care becomes an important 
decision criterion in many health care settings.1 Postoperative 
complications and associated prolonged length of hospi-
tal stay are predominant drivers of total in-hospital costs.2,3 
Strategies reducing postoperative complications are there-
fore of major interest for the patient’s benefit as well as for 
economic reasons. Such strategies also include perioperative 
anesthesia management.
The availability of a short-acting, well-controllable 
IV anesthetic agent such as propofol might influence the 
anesthesiologists to favor total IV anesthesia over inhala-
tional agents. This preference is further supported by con-
cerns about postoperative nausea and vomiting,4 about 
potentially harmful effects by occupational exposure5,6 
(resulting in the need of gas-scavenging systems), and 
about potential environmental pollution caused by vola-
tile anesthetics.7
Volatile anesthetics, however, have been shown to be 
beneficial in scenarios of ischemia–reperfusion injury.8,9 
Data of a longitudinal study of 34,310 coronary artery 
bypass graft interventions show that inhalation anesthe-
sia improves survival.10 Similar results have been found in 
patients undergoing lung surgery: the administration of 
volatile anesthetics during 1-lung ventilation immunomod-
ulated hypoxia/reoxygenation-induced tissue damage and 
resulted in a better postoperative outcome defined by fewer 
postoperative complications.11,12 However, there are also 
studies in which volatile anesthetics failed to exert beneficial 
effects.13–15 As a result of this, and the fact that the underly-
ing molecular mechanisms of the protective effects are cur-
rently only partially understood, the clinical relevance of 
pre-/postconditioning with volatile anesthetics remains still 
controversial.
BACKGROUND: Pharmacologic pre- and postconditioning with sevoflurane compared with total 
IV anesthesia in patients undergoing liver surgery reduced complication rates as shown in 2 
recent randomized controlled trials. However, the potential health economic consequences of 
these different anesthesia regimens have not yet been assessed.
METHODS: An expostcost analysis of these 2 trials in 129 patients treated between 2006 
and 2010 was performed. We analyzed direct medical costs for in-hospital stay and compared 
pharmacologic pre- and postconditioning with sevoflurane (intervention) with total IV anesthesia 
(control) from the perspective of a Swiss university hospital. Year 2015 costs, converted to US 
dollars, were derived from hospital cost accounting data and compared with a multivariable 
regression analysis adjusting for relevant covariables. Costs with negative prefix indicate sav-
ings and costs with positive prefix represent higher spending in our analysis.
RESULTS: Treatment-related costs per patient showed a nonsignificant change by −12,697 US 
dollars (95% confidence interval [CI], 10,956 to −36,352; P = .29) with preconditioning and by 
−6139 US dollars (95% CI, 6723 to −19,000; P = .35) with postconditioning compared with the 
control group. Results were robust in our sensitivity analysis. For both procedures (control and 
intervention) together, major complications led to a significant increase in costs by 86,018 US 
dollars (95% CI, 13,839-158,198; P = .02) per patient compared with patients with no major 
complications.
CONCLUSIONS: In this cost analysis, reduced in-hospital costs by pharmacologic conditioning 
with sevoflurane in patients undergoing liver surgery are suggested. This possible difference 
in costs compared with total IV anesthesia is the result of reduced complication rates with 
pharmacologic conditioning, because major complications have significant cost implications. 
(Anesth Analg 2017;124:925–33)
Economic Evaluation of Pharmacologic Pre- and 
Postconditioning With Sevoflurane Compared With 
Total Intravenous Anesthesia in Liver Surgery: 
A Cost Analysis
Klaus Eichler, MD, MPH,* Martin Urner, MD,† Claudia Twerenbold, MD,*† Sabine Kern,*  
Urs Brügger, PhD,† Donat R. Spahn, MD,† Beatrice Beck-Schimmer, MD,† and Michael T. Ganter, MD‡
From the *Winterthur Institute of Health Economics, Zurich University of 
Applied Sciences, Winterthur, Switzerland; †Institute of Anesthesiology, 
University of Zurich, Zurich, Switzerland; and ‡Institute of Anesthesiology 
and Pain Medicine, Kantonsspital Winterthur, Winterthur, Switzerland.
Accepted for publication November 10, 2016.
Funding: This study is supported by Swiss National Science Foundation 
grant 32003B_135591.
Conflicts of Interest: See Disclosures at the end of the article.
Klaus Eichler, MD, MPH, and Martin Urner, MD, are co-first authors.
Reprints will not be available from the authors.
Address correspondence to Klaus Eichler, MD, MPH, Winterthur Institute of 
Health Economics, Zurich University of Applied Sciences, Gertrudstrasse 15, 
PO Box, CH 8401 Winterthur, Switzerland. Address e-mail to eich@zhaw.ch.
 ORIGINAL CLINICAL RESEARCH REPORT
Copyright © 2017 International Anesthesia Research Society. Unauthorized reproduction of this article is prohibited.
926   www.anesthesia-analgesia.org ANESTHESIA & ANALGESIA
Economic Analysis of Pharmacologic Pre-/Postconditioning
In 2 recent randomized controlled trials (RCTs), phar-
macologic pre- and also postconditioning with volatile 
anesthetics has now been featured as promising hepatopro-
tective strategies in elective liver surgery.16,17 In these stud-
ies, preconditioning with sevoflurane substantially reduced 
the overall complication rate as well as the rate of major 
complications in patients undergoing liver resection. For 
the postconditioning approach, results were similar.17
The economic effect of complications of major gastroin-
testinal surgical procedures such as pancreas or liver surgery 
on hospital treatment costs is well described.3 However, we 
are not aware of studies that assessed the health economic 
effects of pre- or postconditioning with volatile anesthetics 
to avoid such complications. We hypothesized that inter-
rupting propofol anesthesia and adding a short pharmaco-
logic pre- or postconditioning with the volatile anesthetic 
sevoflurane leads to reduced treatment costs in patients 
undergoing liver surgery in a tertiary center compared with 
total IV anesthesia without pharmacologic conditioning. 
Thus, we performed an expostcost analysis of these 2 pub-
lished RCTs.16,17
METHODS
We used data of 2 published RCTs that were approved by 
the institutional review board for human studies and inter-
nationally registered at Clinical Trials.gov NCT0051671116 
and NCT00518908.17 Written informed consent had been 
obtained from all subjects. According to the regional ethical 
board, no additional ethical approval was needed for this ex 
post health economic analysis.
Design and Comparison of Alternatives
A cost analysis was performed focusing on direct medical 
costs for in-hospital stay for patients without liver cirrhosis 
undergoing elective liver resection with inflow occlusion. 
We compared (1) direct medical costs of pharmacologic 
pre- and postconditioning with sevoflurane with (2) direct 
medical costs of total IV anesthesia, the control group in the 
published RCTs.
Setting
The 2 RCTs were conducted at the University Hospital 
Zurich, Zurich, Switzerland. Patients were followed dur-
ing their in-hospital stay. No outpatient data were assessed. 
Consecutive patients without liver cirrhosis undergoing 
elective liver resection with inflow occlusion between April 
2006 and November 200716 and between January 2008 and 
September 201017 were included. All patients undergoing 
laparoscopic liver resection and/or emergency surgery 
(safety concerns) were excluded.
Surgical Intervention
In both RCTs, liver resection was performed with the use 
of the Pringle maneuver. This technique implies clamping 
the hepatic artery and the portal vein to diminish blood 
loss during resection. However, at the same time, the 
maneuver triggers hepatic apoptosis and necrosis known 
as ischemia–reperfusion injury.18,19 The surgical proce-
dures were performed in a standardized manner under 
the supervision of 2 experienced hepatopancreatobiliary 
surgeons and are described elsewhere in detail.16,17 Briefly, 
in the preconditioning setting, the time point of 30 minutes 
before clamping of the portal triad was defined by the sur-
geon while mobilizing the liver and communicated to the 
anesthesiologist. In both clinical trials, inflow occlusion 
was performed using the tourniquet method with a 4-mm 
Mersilene tape applied around the portal triad. The time of 
continuous inflow occlusion lasted for at least 30 minutes 
and was adapted if necessary on request of the surgeon. 
During resections, central venous pressure was adjusted to 
low levels between 0 and 5 mm Hg. All individuals (sur-
geons, nurses, and physicians on the ICU) were blinded for 
group allocation to exclude potential bias. Patients were 
admitted to the ICU according to clear criteria defined by 
institutional standards.
Anesthesia Procedures
Both RCTs had assessed the effect of sevoflurane pre- or 
postconditioning compared with total IV anesthesia. Details 
of the general anesthesia procedures are described in the 
RCT publications.16,17 Briefly, in the control groups, anes-
thetic induction and maintenance were conducted using 
target-controlled infusion of propofol and bolus application 
of fentanyl, remifentanil, and atracurium following a well-
defined protocol according to the clinical needs.
In the intervention groups of both clinical trials, propofol 
anesthesia was replaced by sevoflurane for an overall time 
interval of 30 minutes. In patients with preconditioning, the 
administration of sevoflurane was applied in the 30 minutes 
before hepatic inflow occlusion. In the postconditioning group, 
patients were exposed to sevoflurane immediately on reperfu-
sion of the liver (end of the Pringle maneuver). In both trials, 
propofol infusion was reinitiated when sevoflurane applica-
tion was stopped. In both trials, end-expiratory sevoflurane 
concentrations of 3.2 vol % were targeted during 10 minutes 
(according to a minimal alveolar concentration of 1.5).
The primary clinical outcome of the 2 RCTs was post-
operative alanine aminotransferase or aspartate amino-
transferase peak, which were both significantly reduced 
with pharmacologic pre- or postconditioning. Even more 
important, a relevant clinical benefit of similar magnitude 
emerged in both studies. Fewer complications occurred in 
the intervention group compared with the control group. 
This was the case for any complications (eg, precondi-
tioning: odds ratio, 0.46 [95% confidence interval, {CI}, 
0.25–0.85]; P = .006)16 and for major complications (eg, post-
conditioning: odds ratio, 0.22 [95% CI, 0.05–0.97]; P = .045).17
Subjects and Data Collection
Patients undergoing elective liver resection with inflow 
occlusion were included in the cost analysis. Data of the 2 
RCTs were pooled, because pharmacologic pre- and post-
conditioning implies the same protective principle. For the 
3-arm postconditioning trial,17 we excluded the third ran-
domized group (intermittent clamping group: equivalence 
part of that study) for our cost analysis to isolate the phar-
macologic effect of sevoflurane conditioning.
Data for age, gender, American Society of 
Anesthesiologists physical classification as well as Charlson 
index, reflecting patients’ comorbidities,20 were available. 
Important data from the surgical procedure were used 
such as time of surgery, time of Pringle maneuver, and 
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intraoperative blood loss. Furthermore, length of ICU and 
hospital stay were measured.
For our cost analysis, major complications were defined 
according to the Clavien-Dindo classification (Appendix 
Table A1) as Grade IIIb complications requiring an interven-
tion under general anesthesia, Grade IV complications with 
single- or multiorgan failure, or Grade V defined as death.21 
This outcome is well established via the treatment-oriented 
complication score (www.surgicalcomplication.info).
Health Economic Assessments
Direct health care costs (ie, in-hospital treatment costs, 
including ICU, covering costs for staff and materials) were 
the economic outcome. Indirect costs resulting from loss of 
productivity of patients were not included.
For cost calculations, we applied prospectively collected 
time units (eg, time for nursing and anesthesia services), 
units of other resources (eg, drugs or medical materials), 
and prices via the hospital cost accounting system during 
the study periods (2006–2007 and 2008–2010) that had not 
yet been analyzed for health economic questions. Costs were 
calculated according to Swiss standard procedures for hos-
pital cost accounting.22,23 For example, labor costs for nurses 
are derived by multiplying prospectively documented nurs-
ing time units by current nursing wages; costs for drugs 
(eg, anesthetics) and medical materials (eg, diagnostic tests, 
blood products) are derived by counting units of applied 
resources multiplied by current Swiss unit prices. For the 
intervention itself, this means that sevoflurane costs were 
derived from calculations based on estimated average drug 
volume (6.75 mL for 30 minutes—according to recommen-
dations of the Swiss Society of Anesthesiologists) referring to 
current Swiss prices.24 When adding sevoflurane, the cost for 
propofol was not reduced in our calculation. No additional 
costs were assigned to the intervention, because no supple-
mentary technical equipment or extra staff time was needed. 
Sevoflurane costs are part of the cost element “cost medica-
tion and materials” and are reported separately.
Some additional cost components (eg, for administration) 
are allocated as a fixed rate to each patient. Data for interest 
and capital costs were excluded. We did not rely on hospi-
tal billing data, because at that time, billing data reflected 
the result of negotiations between providers and health 
insurance companies and not costs of resource consump-
tion. None of the patients was hospitalized before surgery to 
receive tests or services directly related to the liver surgery 
under study. Thus, no additional costs were included.
We performed 3 sensitivity analyses: We excluded 
patients who had died (complication Grade V), because 
they might show relatively low costs as a result of a some-
times rapid fatal clinical course. In addition, we excluded 2 
outliers with extremely high costs and patients with minor 
complications.
For the health economic evaluation, we chose the per-
spective of the University Hospital Zurich, because the 
RCTs were performed with patients from that hospital. The 
Swiss prices from 2006 to 2010 were inflated to 2015 Swiss 
prices using the annual rates of the medical component of 
the Swiss consumer price index.25 All costs are presented 
in 2015 US dollars (applying the official 2015 currency 
conversion rate of 1.04 to convert 2015  Swiss Francs (CHF) 
into 2015 US dollars).26 Current standards for performing 
health economic evaluations were applied.27,28
Statistical Analysis
For our descriptive analysis, we used means (standard devi-
ation) or medians (interquartile range [IQR]) for continuous 
variables and proportions for categorical data. For inferen-
tial analysis of cost data, we calculated 95% CI29 as a mea-
sure of uncertainty using the nonparametric bootstrap with 
2000 replicates.30 This resampling method is recommended 
for analysis of means of skewed cost data.30 For other data, 
we applied standard parametric and nonparametric tests, 
as suitable.
For our cost comparison, we used a stepwise approach: 
First, cost data were assigned to each patient. Second, 
we calculated the mean treatment costs for both groups. 
Third, a multivariable linear regression model was used 
to assess the association between costs (dependent vari-
able) and treatment (ie, intervention vs control) adjusting 
for confounding factors. We used 2 data sets of different 
time periods with a slightly different intervention (pre- and 
postconditioning). To take this into account and to adjust for 
unobserved factors that might have differed between trials, 
we introduced a dummy variable for mode of condition-
ing and an interaction term with the treatment. The fit of 
the model was optimized by forming classes over age and 
Charlson index. Akaike information criterion statistics was 
used to avoid overadjustment. In the final model, American 
Society of Anesthesiologists class and Charlson index were 
kept as confounding factors.
Blinding for group allocation in the preconditioning trial 
was applied for the hospital cost accounting team as well as for 
health economic analysts. The code for group allocation had 
not been broken before the cost analysis was finished. For the 
postconditioning trial, the hospital cost accounting team was 
blinded for group allocation, whereas blinding of the health 
economic analysts was not possible. Data analysis was con-
ducted with the STATA SE 14 software package (StataCorp, 
2014; Stata Statistical Software, College Station, TX).
RESULTS
Included Patients and Clinical Course
Overall, 129 patients were analyzed (Figure  1) including 
data of 64 patients from the preconditioning trial (n = 30 
intervention group; n = 34 control group)16 as well as of 65 
patients from the postconditioning trial (n = 48 intervention 
group; n = 17 control group).17 Baseline data and intraopera-
tive characteristics of all 129 patients showed that patients 
randomized to the intervention were somewhat younger, 
but they had a somewhat higher mean Charlson index 
(Table 1). Blood loss was reduced in the intervention group, 
but the difference was not statistically significant.
Significantly fewer complications occurred in the inter-
vention group compared with the control group (any com-
plication: 28% vs 67%; absolute risk reduction [ARR] 39% 
[95% CI, 22–55]; number needed to treat [NNT] 3 [95% CI, 
2–5]; P < .001; Table  2). Also the rate of major complica-
tions (defined as Class IIIb–V) decreased significantly in the 
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intervention group (major complications: 6% vs 24%; ARR 
18% [95% CI, 4–30]; NNT 6 [95% CI, 4–24]; P = .005).
Mean total hospital stay (ie, ICU stay plus floor stay) was 
significantly shorter in the intervention group compared 
with the control group (11.0 vs 13.6 days; absolute differ-
ence: −2.6 days; P = .02; Table 2). In the control group, twice 
as many patients had to be treated postoperatively in an 
ICU (9 of 51 vs 4 of 78 patients). For the preconditioning 
group, the shorter hospital stay of the intervention group 
was mainly because of shorter ICU stay (mean ICU stay: 0.5 
vs 1.7 days; −1.2 days; P = .16; floor stay: 10.5 vs 11.1; −0.6 
days; P = .53). Data for length of ICU stay were not available 
for the postconditioning patients.
Costs
Mean treatment-related costs (Table  3) were lower for 
patients in the intervention group (unadjusted mean costs 
$41,439 [median: 28,588; IQR, 20,928–39,340]) compared 
with the control group (unadjusted mean costs $44,454 
[median: 27,812; IQR, 21,560–46,413]). Main cost com-
ponents were costs for physician and nursing wages, for 
Table 1.  Baseline Data and Intraoperative 
Characteristics of Patients
 
Intervention Control
P Value(n = 78) (n = 51)
Gender
  Men, no. (%) 44 (56.4) 31 (60.8) .62
Age
  Years, mean (SD) 57.5 (13.4) 57.8 (12.8) .90
ASA
  Mean (SD) 2.20 (0.54) 2.22 (0.54) .81
  Class I/II/III (no.) 5/53/20 3/34/14 .97
Charlson index (0–37)
  Mean (SD) 4.95 (2.7) 4.61 (2.8) .69
Duration of operation
  Min, mean (SD) 278 (81.6) 283 (99.8) .76
Duration of Pringle maneuver
  Min, mean (SD) 34 (7.6) 35 (7.0) .86
Blood loss
  mL (SD) 310 (296) 353 (320) .30
Abbreviations: ASA, American Society of Anesthesiologists physical 
classification; Charlson index, reflecting patients’ comorbidities (with higher 
scores indicating higher predicted 10-year mortality); ICU, intensive care unit; 
SD, standard deviation.
Figure 1. Flow of participants through study. The prospectively collected clinical and cost data of 2 published randomized controlled trials 
were used.16,17 For the postconditioning trial population, the intermittent clamping group (equivalence part of that study) was excluded to 
isolate the pharmacologic effect of sevoflurane conditioning. PRE indicates preconditioning trial; POST, postconditioning trial.
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medication and materials as well as for technical services in 
both groups. Estimated costs of the intervention itself were 
$6.38 per patient.
After adjustment for relevant covariables with a mul-
tivariable regression analysis, treatment-related costs in 
the intervention group showed a nonsignificant change 
by $−12,697 (95% CI, 10,956 to −36,352; P = .29) with pre-
conditioning and by $−6139 (95% CI, 6723 to −19,000; 
P = .35) with postconditioning. No significant cost dif-
ference emerged between the pre- and postconditioning 
interventions (P = .84).
Predictors of costs were a higher American Society of 
Anesthesiologists (ASA) score (reference: ASA I; ASA II: P = 
.01; ASA III: P = .02) as well as a high Charlson index (refer-
ence: Charlson ≤3; Charlson > 10: P < .001). The suggested 
difference in treatment costs between intervention and con-
trol group (with postconditioning: $−6,100; with precondi-
tioning $−12,700) was equivalent to about 13% or 27% of 
treatment related costs of the control group.
Distribution of costs showed 2 extreme outliers with 
costs of more than $230,000. One patient in the interven-
tion group (postconditioning) showed costs of $616,153. 
This patient was in the hospital for 74 days, including ICU 
care (main complication: IVb; additional complications: IVa, 
IVa, and IIIa). Similarly, 1 patient in the control group of the 
preconditioning trial showed costs of $371,325. This patient 
was in the hospital for 45 days, of which 30 days were with 
ICU care (main complication: IVb; additional complica-
tions: IVa, IIIb, and II).
Increasing severity of complications was related to 
increasing costs as a general trend (Table 4). Although minor 
complications contributed little to increased costs compared 
with patients with no complications, major complications 
Table 3.  Costs
 Intervention Control
Costs (mean [SD], if not 
indicated otherwise) n = 78 n = 51
Total treatment-related  
costs ($)a
Mean (SD), unadjusted value
41,439 (69,283) 44,454 (54,370)
Costs physician wages ($) 9207 (22,150) 9952 (15,129)
Costs nursing ($) 9526 (23,015) 10,226 (15,488)
Costs medication and 
materials ($)
7979 (10,584) 8025 (8517)
Thereof, costs of sevoflurane 
(intervention; $)
6.38 …
Costs devices ($) 120 (399) 353 (1773)
Costs other nonhospital 
services ($)
176 (878) 90 (213)
Costs hotellerie ($) 1147 (1088) 1273 (1419)
Costs technical services ($)b 9333 (7618) 10,580 (10,766)
Costs administration ($) 3953 (5672) 3954 (4717)
Preconditioning intervention:
Cost reduction for treatment- 
related costs ($)
Mean (95% CI); adjusted 
value,c compared with 
control
−12,697 (10,956 to −36,352);  
P = .29
Postconditioning intervention:
Cost reduction for treatment- 
related costs ($)
Mean (95% CI); adjusted 
value,c compared with 
control
−6139 (6723 to −19,000);  
P = .35
Abbreviations: CI, confidence interval; SD, standard deviation.
aTreatment-related costs include all costs during the index hospitalization for 
liver surgery: physician and nursing wages, surgery, anesthesia, diagnostics, 
drugs, blood products, devices, other materials, ICU care, ward care, costs for 
other technical services, and administration. $ = US dollars.
 bTechnical services include operation theater, intensive care unit, emergency 
ward, radiologic services, laboratory services, diagnostic services, and allied 
health professionals such as occupational therapists, physiotherapists.
cMultivariable linear regression model.
Table 4.  Treatment-Related Costs According to 
Complication Category
 
Total Treatment- 
Related Costs ($)a 
(unadjusted values)
Mean (SD)
 (n = 129)
All patients (n = 129) 42,632 (63,596)
Without complicationsb (n = 73) 28,720 (16,886)
With minor complicationsb (I–IIIa; n = 39) 36,116 (14,973)
With major complicationsb (IIIb–V; n = 17) 117,313 (153,714);  
P = .02c
Abbreviation: SD, standard deviation.
aTreatment-related costs include all costs during the index hospitalization for 
liver surgery: physician and nursing wages, surgery, anesthesia, diagnostics, 
drugs, blood products, devices, other materials, intensive care unit care, ward 
care, costs for other technical services, and administration. $ = US dollars.
bAccording to the Clavien-Dindo classification.
cCompared with “no major complication” (ie, “without complication” or “with 
minor complications”).
Table 2.  Complications and Length of Stay
 
Intervention Control Absolute Risk Reductiona 
(95% CI)
Number Needed to Treat 
(95% CI) P Value(n = 78) (n = 51)
Complications
  Any, no. (%) 22 (28) 34 (67) 39% (22 to 55) 3 (2 to 5) <.001
  Major (IIIb–V), no. (%) 5 (6) 12 (24) 18% (4 to 30) 6 (4 to 24) .005
Length of hospital stay   Absolute Differencea   
  Days (mean; SD) 11.0 (8.6) 13.6 (8.6) −2.6 (8.7)  .02b
Length of ICU stayc
  Days (mean; SD) 0.5 (2.0) 1.7 (5.4) −1.2 (4.2)  .16b
Length of floor stayc
  Days (mean; SD) 10.5 (2.0) 11.1 (5.4) −0.6 (5.1)  .53b
Abbreviations: CI, confidence interval; ICU, intensive care unit; SD, standard deviation.
aIntervention versus control.
bWilcoxon rank-sum test (intervention vs control).
cData available for 64 patients with preconditioning (n = 30 intervention; n = 34 control); thus, data may not add up to “length of hospital stay.”
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were a substantial cost driver. This also held when pre- and 
postconditioning data were depicted for intervention and 
control patients separately (Table 5). Patients without major 
complications (n = 112) showed average costs of $31,296 
(standard deviation 16,559), but costs increased consid-
erably if major complications occurred (mean: $117,314 
[standard deviation 153,714]; n = 17). Such a difference of 
$86,018 (95% CI, 13,839–158,198; P = .02) is highly relevant 
for hospitals.
In our sensitivity analysis, the results of the main analysis 
showed to be robust (Appendix Table A2). However, the 
exclusion of 39 patients with minor complications led to in-
creased costs in the postconditioning intervention group of 
$2501 [95% CI, 22,585 to −17,584]; P = .81) compared with 
the control group as a result of the increased weight of 1 pa-
tient in the postconditioning intervention group with major 
complications and extremely high costs of $616,153.
DISCUSSION
The present cost analysis suggests that pre- and postcondi-
tioning with sevoflurane can result in relevant cost savings 
when compared with total IV anesthesia in patients under-
going elective liver resection with inflow occlusion. Major 
complications had a significant effect on costs.
Strengths and Limitations of Our Approach
Our study shows several methodological strengths: (1) All 
consecutive patients of a single tertiary center who met the 
inclusion criteria were included in the trial. This contrib-
utes to the external validity of results for other centers with 
specialized hepatic surgery. (2) Both trials show a clinical 
effect of similar magnitude. (3) Our statistical model takes 
into account the fact that data are derived from 2 trials per-
formed at different time points (2006–2007 and 2008–2010) 
and adjusts for unobserved differences in postoperative 
care and cost accounting over time. This makes our findings 
more robust.
Several methodological limitations have to be men-
tioned: First, applied data are from the period 2006 to 2010. 
However, we adjusted cost data for inflation until 2015 
using the medical component of the Swiss consumer price 
index. Second, the available sample size is underpowered 
for a health economic analysis, because the sample sizes 
of the 2 RCTs were calculated for a biochemical marker as 
the primary endpoint (alanine aminotransferase, aspartate 
aminotransferase) and not for a cost outcome. At a bigger 
sample size, it is more likely that the demonstrated differ-
ence in total treatment-related costs becomes statistically 
significant as well. Finally, despite a suitable randomiza-
tion procedure in both trials, an imbalance in some of the 
confounding patient parameters emerged between groups, 
presumably because of the small sample size. However, 
we applied a suitable statistical adjustment for relevant 
confounders in our model to overcome possible bias.
Protective Effects of Volatile Anesthetics
The clinical relevance of the protective effects provided by 
volatile anesthetics is the subject of an ongoing debate that 
has lasted for 3 decades.31 In cardiac surgery, the use of vola-
tile anesthetics is associated with a reduced risk of all-cause 
mortality and of myocardial infarction.32 Beside the benefi-
cial effects in liver surgery, there is also sound evidence on 
neuroprotection and protection exerted by volatile anes-
thetics against ischemic acute kidney injury.33,34 However, in 
a large study comparing volatile anesthetics versus total IV 
anesthesia, no overall benefit for patients undergoing non-
cardiac surgery could be demonstrated.35 In addition, there 
is also solid concern about increased apoptosis and forma-
tion of β-amyloid protein in neuronal tissue induced by 
volatile anesthetics.36 The reason for this contradictory evi-
dence base is that the underlying molecular mechanisms are 
currently not understood fully.37 Several mechanisms have 
been proposed, which might be responsible for the benefi-
cial effects such as a different regulation of energy metabo-
lism mediated by mitochondrial potassium channels38 and/
or a modulation of effector cell adhesion39 and function40,41 
induced by volatile anesthetics. There is also some evidence 
that not the ether basic structure, but parts of the halogena-
tion of volatile anesthetics and of their metabolites might be 
responsible for altered host response to tissue injury.42
In this study, we investigated the effects of sevoflurane 
pre- and postconditioning and might therefore not be able 
to generalize the results for all volatile anesthetics. Also, in 
both RCTs, the patients were exposed to sevoflurane dur-
ing a time period of only 30 minutes. In other studies, how-
ever, volatile anesthetics were used for the entire duration 
of the anesthesia and no protective effects compared with 
propofol anesthesia were observed. This suggests that the 
duration of exposure to volatile anesthetics might be a cru-
cial factor with regard to the exertion of potential protective 
Table 5.  Treatment-Related Costs According to Major Complications
 Intervention Control
 
Major Complicationsa 
No
Major Complicationsa 
Yes
Major Complicationsa 
No
Major Complicationsa 
Yes
Preconditioning trial (n = 30 and n = 34; N = 74)
Total treatment-related costs ($)b
n = 28
32,054
n = 2
74,878
n = 25
25,253
n = 9
104,021
Postconditioning trial (n = 48 and n = 17; N = 65)
Total treatment-related costs ($)b
n = 45
31,813
n = 3
251,151
n = 14
38,910
n = 3
51,643
All patients (n = 78 and n = 51; N = 129)
Total treatment-related costs ($)b
n = 73
31,906
n = 5
180,642
n = 39
30,155
n = 12
90,927
aMajor complications include complication Classes IIIb–V according to the Clavien-Dindo classification; “major complications no” include patients with no 
complications or with minor complications.
bTreatment-related costs include all costs during the index hospitalization for liver surgery: physician and nursing wages, surgery, anesthesia, diagnostics, drugs, 
blood products, devices, other materials, intensive care unit care, ward care, costs for other technical services, and administration.
$ = US dollars; costs are unadjusted, mean treatment-related costs.
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effects (on/off vs exposure during entire procedure).43–45 In 
addition, only the beneficial effects, most probably, become 
apparent in patients who have been exposed to a relevant 
ischemia–reperfusion or hypoxia/reoxygenation injury.
The ARR of major complications was 18% (95% CI, 4–30) 
resulting in a NNT of 6 patients. Major complications, how-
ever, are a significant cost driver, as shown in our study 
and also for liver surgery in a previous publication.3 Thus, 
besides the avoidance of detrimental effects for patients, pre-
vention of complications is of high economic importance. In 
contrast, direct costs of anesthesia with volatile anesthetics 
range at very low prices between $12 and $23 per hour.46,47 
We are not aware of another health economic evaluation, 
which has assessed the economic effects of pharmacologic 
conditioning with volatile agents in major surgical interven-
tions. Graham et al48 have performed health economic evalu-
ations assessing the economic effect of N2O-free anesthetics. 
Their cost–benefit analysis showed lower treatment costs 
resulting from lower complication rates, although the costs 
of N2O-free anesthetics were higher when compared with the 
conventional procedures with N2O.48 More health economic 
evaluations have to be performed to better understand the 
relationship between the magnitude of patient benefit and 
costs for innovative approaches in anesthesia. Patient blood 
management, for example, could be such an approach to be 
evaluated with sound health economic analyses.49
Significance of Findings for Patients and 
Implications for Decision-Makers
Our results can primarily inform health care decision-
makers within the implementing hospital as well as local 
authorities about the costs of service provision not only in 
Switzerland, but internationally. Nevertheless, it is worth 
noting that our results of the in-hospital cost accounting is 
specific to a Swiss (European) system, where the patient is 
more likely to stay for a longer portion of recovery as com-
pared with the United States, which emphasizes more rapid 
discharge to an intermediate level of care such as a rehabili-
tation hospital or an according nursing facility. In addition, 
variation in the cost pattern between hospitals may exist 
because of variable organizational processes, even within 
a single country. Although in our data set, the difference 
in costs between intervention and control groups was not 
statistically significant, such cost savings are economically 
relevant, because they add up to a substantial sum after 
repeated treatments. Using a clinical example, clinicians 
(as health economists and decision-makers) are interested 
in clinically (financially) relevant differences rather than in 
statistically significant differences that are not relevant for 
patients (payers).
No need for further education of the staff or acquisition 
of new equipment is necessary for pharmacologic condition-
ing. This is an additional advantage. Thus, for clinicians and 
the hospital management, promotion of pharmacologic pre- 
or postconditioning in liver surgery is an attractive option 
to contemporaneously optimize patient care and resource 
utilization. Particularly the postconditioning approach rep-
resents a feasible method, which does not require detailed 
planning like in preconditioning, in which the window of 
sevoflurane application has to be coordinated with the surgi-
cal partner. Also in emergency situations, postconditioning 
can be performed, whereas preconditioning might not be an 
option.
CONCLUSIONS
In this cost analysis, reduced in-hospital costs by pharma-
cologic conditioning with sevoflurane in patients undergo-
ing liver surgery are suggested. This possible cost difference 
is the result of reduced complication rates, because major 
complications have significant cost implications. These 
findings can feed the discussion with authorities to allow 
clinicians to design best practice plans for the treatment of 
patients. Such information is becoming more important to 
increase value in health care.1 E
Table A2. Sensitivity Analysis
 
Cost reduction for  
treatment-related costs ($)a
Mean (95% CI); adjusted valueb
Complete study population (n = 129)
  Preconditioning 
intervention (n = 78)
−12,697 (10,956 to −36,352); P = .29
  Postconditioning 
intervention (n = 51)
−6139 (6273 to −19,000); P = .35
Exclusion of 2 extreme outlier patients with treatment-related costs 
of >$200,000 (n = 127)
  Preconditioning 
intervention (n = 77)
−2771 (9748 to −15,292); P = .66
  Postconditioning 
intervention (n = 50)
−5599 (6272 to −17,471); P = .35
Exclusion of 2 dead patients (n = 127)
  Preconditioning 
intervention (n = 77)
−14,512 (8414 to −37,437); P = .21
  Postconditioning 
intervention (n = 50)
−6550 (6134 to −19,232); P = .31
Exclusion of 39 patients with minor complications (n = 90)
  Preconditioning 
intervention (n = 61)
−23,766 (13,715 to −61,248); P = .21
  Postconditioning 
intervention (n = 29)
+2501 (22,585 to −17,584); P = .81
Abbreviation: CI, confidence interval.
aTreatment-related costs include all costs during the index hospitalization for 
liver surgery: physician and nursing wages, surgery, anesthesia, diagnostics, 
drugs, blood products, devices, other materials, intensive care unit care, ward 
care, costs for other technical services, and administration. $ = US dollars.
bMultivariable linear regression model, intervention compared with control.
Table A1. Complication Grades According to the 
Clavien-Dindo Classification21
Grade Definition
Grade I Any deviation from the normal postoperative course without 
the need for pharmacologic treatment or surgical, 
endoscopic, and radiologic interventions
Grade II Requiring pharmacologic treatment with drugs other than 
such allowed for Grade I complications; blood transfusions 
and total parenteral nutrition are also included
Grade III Requiring surgical, endoscopic or radiological intervention
Grade IIIa Intervention not under general anesthesia
Grade IIIb Intervention under general anesthesia
Grade IV Life-threatening complication (including central nervous 
system complicationsa) requiring IC/ICU management
Grade IVa Single-organ dysfunction (including dialysis)
Grade IVb Multiorgan dysfunction
Grade V Death of patient
Abbreviations: IC, intermediate care; ICU, intensive care unit; TIA, transient 
ischemic attacks.
aBrain hemorrhage, ischemic stroke, subarachnoidal bleeding, but excluding TIA.
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